Log in

CNSX:CALIFincanna Capital Stock Price, Forecast & News

$0.09
0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.09
50-Day Range N/A
52-Week Range N/A
Volume94,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
FinCanna Capital Corp. operates as a royalty investment company for the licensed medical cannabis industry in the United States. The company provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues with a focus on California. The company has royalty agreements with Cultivation Technologies Inc.; Green Compliance Inc.; and Refined Resin Technologies Inc. FinCanna Capital Corp. is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone778-327-5799

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CALI News and Ratings via Email

Sign-up to receive the latest news and ratings for CALI and its competitors with MarketBeat's FREE daily newsletter.

Fincanna Capital (CNSX:CALI) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Fincanna Capital?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fincanna Capital in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fincanna Capital.

What price target have analysts set for CALI?

1 Wall Street analysts have issued 1 year price targets for Fincanna Capital's stock. Their forecasts range from $0.29 to $0.29. On average, they expect Fincanna Capital's stock price to reach $0.29 in the next twelve months. This suggests a possible upside of 222.2% from the stock's current price. View analysts' price targets for Fincanna Capital.

Has Fincanna Capital been receiving favorable news coverage?

Headlines about CALI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fincanna Capital earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutFincanna Capital.

Who are some of Fincanna Capital's key competitors?

Who are Fincanna Capital's key executives?

Fincanna Capital's management team includes the following people:
  • Mr. Andriyko Taras Herchak B.Com., C.A., CPA, CA, Pres, CEO & Director (Age 47)
  • Mr. Robert James Scott, CFO & Director
  • Mr. Jeffrey Dare, Corp. Sec. & Director (Age 39)

What is Fincanna Capital's stock symbol?

Fincanna Capital trades on the CNSX under the ticker symbol "CALI."

How do I buy shares of Fincanna Capital?

Shares of CALI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fincanna Capital's stock price today?

One share of CALI stock can currently be purchased for approximately $0.09.

What is Fincanna Capital's official website?

The official website for Fincanna Capital is www.fincannacapital.com.

How can I contact Fincanna Capital?

The company can be reached via phone at 778-327-5799.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.